^
    3ms
    Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (clinicaltrials.gov)
    P1/2, N=55, Terminated, BioNTech SE | Active, not recruiting --> Terminated; Sponsor decision
    Trial termination • Combination therapy
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • BNT411
    11ms
    Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (clinicaltrials.gov)
    P1/2, N=55, Active, not recruiting, BioNTech SE
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • BNT411
    12ms
    Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (clinicaltrials.gov)
    P1/2, N=55, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • BNT411
    3years
    Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors (SITC 2021)
    P1/2 | "Part 1A is a single-agent dose escalation (accelerated titration) of BNT411 in patients with metastatic or unresectable solid tumors that have exhausted available treatment options, with bifurcation to Part 1B, a dose escalation of BNT411 in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC), followed by expansion cohorts (Part 2). Updated data will be presented, including combination treatment in the first-line setting of ES-SCLC. Trial Registration Clinicaltrials.gov: NCT04101357"
    PK/PD data • P1/2 data • Clinical
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • BNT411